Regional Insights North America GLP-1 Receptor Agonist Market Trends North America dominates the GLP-1 receptor agonist market with a 41.8% share in 2025 , driven by the high prevalence of diabetes and obesity, coupled with strong healthcare infrastructure and widespread insurance coverage
6 In a randomized, controlled, crossover study in healthy subjects, consuming 180 mg of curcumin before a carbohydrate-rich meal significantly reduced the incremental area under the curve for plasma glucose over 120 minutes by approximately 36 percent compared with control, without major adverse events
Compared to usual care, GLP-1RA use was linked to: Neurological & Psychiatric Benefits Reduced risk of substance use disorders (alcohol, cannabis, opioids, and stimulants)
Gastrointestinal Side Effects Over Time Nausea, vomiting, diarrhea, and constipation are the most common side effects of GLP-1 therapy
They are approaches that align with the biology of gut adaptation and that users consistently report as helpful
To address this vital question, the next step should involve undertaking further prospective clinical trials
